TABLE 1.
Patient characteristics at study entry
| Parameter | All (N = 225) | Seropositive (N = 56) | Seronegative (N = 169) |
|---|---|---|---|
| Age, y | 62 (54–70) | 61 (57–68) | 62 (53–70) |
| M:F | 1:0.5 | 1:0.6 | 1:0.5 |
| Time after transplantation, mo | 81 (31–148) | 150 (94–227) | 56 (26–124)** |
| Creatinine, mg/dl | 1.6 (1.2–2.0) | 1.6 (1.2–1.9) | 1.5 (1.2–2.1) |
| eGFR, ml/min/1.73 m2 | 45 (31–58) | 45 (31–61) | 45 (31–58) |
| Immunosuppression | |||
| CNI | 217 (96.4%) | 54 (96.4%) | 163 (96.4%) |
| Steroids | 212 (94.2%) | 51 (91.1%) | 161 (95.3%) |
| mTOR inhibitor | 7 (3.1%) | 4 (7.1%) | 3 (1.8%) |
| Azathioprine | 4 (1.8%) | 2 (3.6%) | 2 (1.2%) |
| Belatacept | 5 (2.2%) | 0 (0%) | 5 (3%) |
| MMF | 187 (83.1%) | 26 (46.4%) | 161 (95.3%)** |
| ≤1 g/d | 119 (63.6%) | 23 (88.5%) | 96 (59.6%)** |
| ≥1 g/d | 68 (36.4%) | 3 (11.5%) | 65 (40.4%)** |
| Dual therapy | 39 (17.3%) | 26 (46.4%) | 13 (7.7%)** |
| With MMF | 12 (30.8%) | 3 (11.5%) | 9 (69.2%)** |
| No MMF | 27 (69.2%) | 23 (88.5%) | 4 (30.8%)** |
| Triple therapy | 184 (81.8%) | 28 (50%) | 156 (92.3%)** |
| With MMF | 175 (95.1%) | 23 (82.1%) | 152 (97.4%)** |
| No MMF | 9 (4.9%) | 5 (17.9%) | 4 (2.6%)* |
| Monotherapy | 2 (0.9%) | 2 (3.6%) | 0 (0%) |
Note: Seropositivity was defined as IgG antibody against SARS-CoV-2 spike S1 subunit titer above 35.2 BAU/ml measured 2 weeks after the second vaccine dose. Dichotomous data are presented as percentages whereas continuous data as means ± SD or median (Q1–Q3).
Abbreviations: CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate; MMF, mycophenolate mofetil.
***
Represent significant difference between the groups with p < .001.
**
p < .01.
*
p < .05 using Chi-square test or Mann–Whitney test.